-
Posted by
Two Blokes May 20 -
Filed in
Stock
-
2 views
VKTX's VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. The company's phase 3 program on subcutaneous VK2735 is getting underway, although given it will contain thousands of patients, a readout isn't a near-term prospect. VKTX will evaluate once-monthly maintenance dosing of VK2735 in 2025, which could allow it to confirm it can compete with the likes of agents from AMGN and MTSR.
